Cetus Healthcare Limited Partnership II
Executive Summary
Public offering of shares in the $100 mil. R&D partnership began Oct. 30. Proceeds will be used to fund the development of therapeutic products in Europe through the company's new subsidiary, EuroCetus ("The Pink Sheet" Aug. 25, T&G-2). Shearson Lehman Brothers and Oppenheimer are managing the sale.